A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Phase 3 Completed 256 enrolled Amgen

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to investigate the pharmacokinetic (PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma.

Timeline

Start: 2023-07-26
Primary completion: 2025-03-26
Completion: 2025-10-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Nivolumab	Monoclonal antibody	—	Intravenous

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Summary

Timeline

Drugs

Indications